Prelude Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Prelude Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-7,800	Closed	-$17K	–	2004
2017 Q3	$17K	Buy	7,800 +5,600	+255%	+$13.7K	﹤0.01%	1354
2017 Q2	$6K	Buy	+2,200	New	+$6.6K	﹤0.01%	1461
2016 Q1	–	Sell	-2,730	Closed	-$47K	–	1808
2015 Q4	$47K	Hold	2,730	–	–	0.01%	1061
2015 Q3	$58K	Buy	2,730 +1,540	+129%	+$52.8K	0.01%	1016
2015 Q2	$59K	Buy	1,190 +690	+138%	+$41.3K	0.01%	1105
2015 Q1	$39K	Buy	+500	New	+$31K	0.01%	1471

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Prelude Capital Management's OREX Position: Q4 2017 in Review

Prelude Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 7,800 shares — an estimated $17K sold.

Prelude Capital Management first reported a position in OREX in Q1 2015 and held it in 6 quarters. The position peaked at $59K in Q2 2015. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

Prelude Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Prelude Capital Management sold 7,800 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $17K.
Prelude Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 6 quarters.
Prelude Capital Management's Orexigen Therapeutics, Inc. position peaked at $59K in Q2 2015.
41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.